The anti-inflammatory mechanisms of GLP-1 medications appear to involve multiple pathways in experimental models
These medications are designed to act on pathways associated with the GLP-1 hormone, which is naturally released in the gastrointestinal tract after eating
Demand keeps growing, but qualified production capacity does not expand overnight
The American Association of Clinical Endocrinologists/American College of Endocrinology consensus statement also recommends either a GLP-1RA or SGLT2i as a preferred treatment option (either as first-line or, more typically, second-line treatment after metformin) over alternative options such as a dipeptidyl peptidase-4 inhibitor, a thiazolidinedione (TZD), or a sulfonylurea (SU), for patients with T2D and ASCVD, stage 3 CKD, or heart failure with reduced ejection fraction [2]
Our mission is to empower you with the knowledge to make confident, informed decisions
Published 2023 Oct 17